Literature DB >> 20164419

Detailed characterization of T cell responses to herpes simplex virus-2 in immune seronegative persons.

Christine M Posavad1, Michael Remington, Dawn E Mueller, Lin Zhao, Amalia S Magaret, Anna Wald, Lawrence Corey.   

Abstract

In 2003, we described a small cohort of subjects (n = 6) who possessed no detectable serum Abs to HSV-1 or HSV-2 and no clinical or virological evidence of mucosal HSV infection yet possessed consistently detectable HSV-specific T cell responses measured primarily by lymphoproliferative (LP) and CTL assays to whole HSV-2 Ag. We termed these persons immune seronegative (IS). This report characterizes the T cell responses in 22 IS subjects largely recruited from studies of HSV-seronegative subjects in ongoing sexual relationships with HSV-2-seropositive (HSV-2(+)) partners using pools of overlapping peptides spanning 16 immuno-prevalent HSV-2 proteins. Overall, 77% of IS subjects had HSV-specific LP responses, 85% had IFN-gamma ELISPOT responses to at least one HSV-2 peptide pool, and 55% had both LP and IFN-gamma ELISPOT responses. In some cases, IFN-gamma ELISPOT responses were in excess of 500 spot-forming cells per 10(6) PBMCs and persisted for over 5 y. Although HSV-2(+) subjects (n = 40) had frequent responses to glycoproteins and tegument and immediate-early (IE) proteins of HSV-2, T cell responses in IS subjects were directed primarily at UL39 and the IE proteins ICP4 and ICP0. These data suggest that the antigenic repertoire of T cells in IS subjects is skewed compared with that of HSV-2(+) subjects and that IS subjects had more frequent T cell responses to IE proteins and infrequent T cell responses to virion components. Understanding the mechanism(s) by which such responses are elicited may provide important insights in developing novel strategies for preventing acquisition of sexually acquired HSV-2.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20164419      PMCID: PMC2877513          DOI: 10.4049/jimmunol.0900722

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  31 in total

1.  T cell immunity to herpes simplex viruses in seronegative subjects: silent infection or acquired immunity?

Authors:  Christine M Posavad; Anna Wald; Nancy Hosken; Meei Li Huang; David M Koelle; Rhoda L Ashley; Lawrence Corey
Journal:  J Immunol       Date:  2003-04-15       Impact factor: 5.422

2.  Severe genital herpes infections in HIV-infected individuals with impaired herpes simplex virus-specific CD8+ cytotoxic T lymphocyte responses.

Authors:  C M Posavad; D M Koelle; M F Shaughnessy; L Corey
Journal:  Proc Natl Acad Sci U S A       Date:  1997-09-16       Impact factor: 11.205

3.  CD8(+) lymphocytes respond to different HIV epitopes in seronegative and infected subjects.

Authors:  R Kaul; T Dong; F A Plummer; J Kimani; T Rostron; P Kiama; E Njagi; E Irungu; B Farah; J Oyugi; R Chakraborty; K S MacDonald; J J Bwayo; A McMichael; S L Rowland-Jones
Journal:  J Clin Invest       Date:  2001-05       Impact factor: 14.808

4.  Cellular immune responses in seronegative sexual contacts of acute hepatitis C patients.

Authors:  Sanaa M Kamal; Ashraf Amin; Mohamed Madwar; Camilla S Graham; Qi He; Ahmed Al Tawil; Jens Rasenack; Tatsunori Nakano; Betty Robertson; Alaa Ismail; Margaret James Koziel
Journal:  J Virol       Date:  2004-11       Impact factor: 5.103

5.  HIV-specific mucosal and cellular immunity in HIV-seronegative partners of HIV-seropositive individuals.

Authors:  S Mazzoli; D Trabattoni; S Lo Caputo; S Piconi; C Blé; F Meacci; S Ruzzante; A Salvi; F Semplici; R Longhi; M L Fusi; N Tofani; M Biasin; M L Villa; F Mazzotta; M Clerici
Journal:  Nat Med       Date:  1997-11       Impact factor: 53.440

6.  HIV-specific cytotoxic T-cell activity in an HIV-exposed but uninfected infant.

Authors:  S L Rowland-Jones; D F Nixon; M C Aldhous; F Gotch; K Ariyoshi; N Hallam; J S Kroll; K Froebel; A McMichael
Journal:  Lancet       Date:  1993-04-03       Impact factor: 79.321

7.  Inaccuracy of certain commercial enzyme immunoassays in diagnosing genital infections with herpes simplex virus types 1 or 2.

Authors:  Rhoda Ashley Morrow; David Friedrich
Journal:  Am J Clin Pathol       Date:  2003-12       Impact factor: 2.493

8.  Cell-mediated immune response to human immunodeficiency virus (HIV) type 1 in seronegative homosexual men with recent sexual exposure to HIV-1.

Authors:  M Clerici; J V Giorgi; C C Chou; V K Gudeman; J A Zack; P Gupta; H N Ho; P G Nishanian; J A Berzofsky; G M Shearer
Journal:  J Infect Dis       Date:  1992-06       Impact factor: 5.226

Review 9.  The effects of herpes simplex virus-2 on HIV-1 acquisition and transmission: a review of two overlapping epidemics.

Authors:  Lawrence Corey; Anna Wald; Connie L Celum; Thomas C Quinn
Journal:  J Acquir Immune Defic Syndr       Date:  2004-04-15       Impact factor: 3.731

10.  Hepatitis C virus-specific T-cell immune responses in seronegative injection drug users.

Authors:  M Zeremski; M A Shu; Q Brown; Y Wu; D C Des Jarlais; M P Busch; A H Talal; B R Edlin
Journal:  J Viral Hepat       Date:  2008-07-17       Impact factor: 3.728

View more
  34 in total

Review 1.  Immunology in the Clinic Review Series; focus on host responses: T cell responses to herpes simplex viruses.

Authors:  K J Laing; L Dong; J Sidney; A Sette; D M Koelle
Journal:  Clin Exp Immunol       Date:  2012-01       Impact factor: 4.330

2.  Preventing sexually transmitted infections: back to basics.

Authors:  Anne Rompalo
Journal:  J Clin Invest       Date:  2011-12-01       Impact factor: 14.808

3.  A Dual-Modality Herpes Simplex Virus 2 Vaccine for Preventing Genital Herpes by Using Glycoprotein C and D Subunit Antigens To Induce Potent Antibody Responses and Adenovirus Vectors Containing Capsid and Tegument Proteins as T Cell Immunogens.

Authors:  Sita Awasthi; Gregory G Mahairas; Carolyn E Shaw; Meei-Li Huang; David M Koelle; Christine Posavad; Lawrence Corey; Harvey M Friedman
Journal:  J Virol       Date:  2015-06-03       Impact factor: 5.103

4.  Development of an interferon-gamma ELISPOT assay to detect human T cell responses to HSV-2.

Authors:  Christine M Posavad; Amalia S Magaret; Lin Zhao; Dawn E Mueller; Anna Wald; Lawrence Corey
Journal:  Vaccine       Date:  2011-07-27       Impact factor: 3.641

5.  Enhanced and efficient detection of virus-driven cytokine expression by human NK and T cells.

Authors:  Laura Pattacini; Pamela M Murnane; Tayler R Fluharty; Elly Katabira; Stephen C De Rosa; Jared M Baeten; Jennifer M Lund
Journal:  J Virol Methods       Date:  2014-01-10       Impact factor: 2.014

Review 6.  Vaccines to prevent genital herpes.

Authors:  Kevin Egan; Lauren M Hook; Philip LaTourette; Angela Desmond; Sita Awasthi; Harvey M Friedman
Journal:  Transl Res       Date:  2020-03-16       Impact factor: 7.012

7.  A Randomized, Double-Blinded, Placebo-Controlled, Phase 1 Study of a Replication-Defective Herpes Simplex Virus (HSV) Type 2 Vaccine, HSV529, in Adults With or Without HSV Infection.

Authors:  Lesia K Dropulic; Makinna C Oestreich; Harlan L Pietz; Kerry J Laing; Sally Hunsberger; Keith Lumbard; Doreen Garabedian; Siu Ping Turk; Aiying Chen; Ronald L Hornung; Chetan Seshadri; Malisa T Smith; Nancy A Hosken; Sanjay Phogat; Lee-Jah Chang; David M Koelle; Kening Wang; Jeffrey I Cohen
Journal:  J Infect Dis       Date:  2019-08-09       Impact factor: 5.226

Review 8.  The challenge of developing a herpes simplex virus 2 vaccine.

Authors:  Lesia K Dropulic; Jeffrey I Cohen
Journal:  Expert Rev Vaccines       Date:  2012-12       Impact factor: 5.217

9.  CD4 T-cell memory responses to viral infections of humans show pronounced immunodominance independent of duration or viral persistence.

Authors:  Lichen Jing; Joshua T Schiffer; Tiana M Chong; Joseph J Bruckner; D Huw Davies; Phillip L Felgner; Juergen Haas; Anna Wald; G M G M Verjans; David M Koelle
Journal:  J Virol       Date:  2012-12-19       Impact factor: 5.103

Review 10.  Varicella zoster vaccines and their implications for development of HSV vaccines.

Authors:  Anne A Gershon
Journal:  Virology       Date:  2013-01-05       Impact factor: 3.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.